A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate Cancer
- Conditions
- Prostate CancerCastration-resistant Prostate CancerMetastatic Prostate Cancer
- First Posted Date
- 2014-02-20
- Last Posted Date
- 2019-12-20
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 1533
- Registration Number
- NCT02066961
- Locations
- π¬π§
Site, Sunderland, United Kingdom
A Study to Evaluate the Pharmacokinetics of BAL8728 After a Single Dose of Pyridinylmethyl-14C-Labeled Isavuconazonium Sulfate in Healthy Male Subjects
- Conditions
- Healthy SubjectsPharmacokinetics of 14C-labeled Isavuconazonium Sulfate
- Interventions
- First Posted Date
- 2014-02-11
- Last Posted Date
- 2014-02-11
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT02059590
- Locations
- πΊπΈ
Covance, Madison, Wisconsin, United States
A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2014-02-07
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT02057380
- Locations
- πΊπΈ
Site US10004, La Jolla, California, United States
πΊπΈSite US10006, Tampa, Florida, United States
πΊπΈSite US10002, Baltimore, Maryland, United States
A Study To Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of ASP2408 After Multiple Dose Subcutaneous Injections in Patients With Rheumatoid Arthritis on Methotrexate
- Conditions
- Pharmacokinetics of ASP2408Rheumatoid Arthritis
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-02-03
- Last Posted Date
- 2014-02-06
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02052375
- Locations
- πΊπΈ
Pinnacle Research Group, LLC, Anniston, Alabama, United States
πΊπΈAltoona Center for Clinical Research, Duncansville, Pennsylvania, United States
πΊπΈMetroplex Clinical Research Center, LLC, Dallas, Texas, United States
Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2013-12-18
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 265
- Registration Number
- NCT02014558
- Locations
- πΊπΈ
Site US10021, Birmingham, Alabama, United States
πΊπΈSite US10023, Scottsdale, Arizona, United States
πΊπΈSite US10022, Duarte, California, United States
A Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP4058 Following Single Oral Doses
- Conditions
- Healthy SubjectsFood Effect of ASP4058Pharmacokinetics of ASP4058
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-12-02
- Last Posted Date
- 2013-12-02
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 130
- Registration Number
- NCT01998646
- Locations
- πΊπΈ
Clinical Pharmacology of Miami, Inc, Miami, Florida, United States
πΊπΈCovance Clinical Research Unit, Inc., Evansville, Indiana, United States
A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide
- Conditions
- Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Interventions
- First Posted Date
- 2013-11-07
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 424
- Registration Number
- NCT01977651
- Locations
- πΊπΈ
Site US10005, Anchorage, Alaska, United States
πΊπΈSite US10024, Detroit, Michigan, United States
πΊπΈSite US10026, Bronx, New York, United States
A Study to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an Organ From a CMV-Seropositive Donor
- Conditions
- Kidney Transplantation Cytomegalovirus (CMV) Negative Recipients
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-11-01
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT01974206
- Locations
- πΊπΈ
Site US10026, Phoenix, Arizona, United States
πΊπΈSite US10003, Los Angeles, California, United States
πΊπΈSite US10004, San Diego, California, United States
ASG-15ME is a Study of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer
- First Posted Date
- 2013-10-16
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 93
- Registration Number
- NCT01963052
- Locations
- πΊπΈ
Site US00006, Birmingham, Alabama, United States
πΊπΈSite US00002, New Haven, Connecticut, United States
πΊπΈSite US00001, Detroit, Michigan, United States
Drug-Drug Interaction Study Evaluating Effects of ASP015K on Rosuvastatin
- Conditions
- Healthy SubjectsPharmacokinetics of ASP015K
- Interventions
- First Posted Date
- 2013-10-10
- Last Posted Date
- 2013-10-10
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01959399
- Locations
- πΊπΈ
PAREXEL - Early Phase Unit, Glendale, California, United States